Search
Filter Results
Displaying 471–480 of 850 results for “vision connection”
-
After a review by our Scientific Advisory Board (SAB), three key research gaps were identified: models to study retinal diseases, understanding how the immune system reacts, and finding biomarkers that can predict disease progression and help guide treatment decisions.
-
Sep 23, 2024
4DMT Planning Phase 3 Clinical Trial for Wet AMD Gene Therapy
Research NewsKnown as 4D-150, the wet AMD gene therapy performed well in a Phase 2b clinical trial.
-
The Cincy Source provides a platform for professionals serving the blind and low vision community in Cincinnati and surrounding areas to showcase services and other resources.
-
Foundation Forums for Blindness
The Foundation Forums for Blindness is a network of professionals serving the blind and low vision community in markets all over the U.S.
-
GoodMaps and Be My Eyes.
-
May 2, 2024
Atsena’s XLRS Gene Therapy Shows Efficacy in Phase 1/2 Clinical Trial
Research NewsThe XLRS gene therapy was well tolerated and resolved damaging schisis cavities in patients receiving the lowest dose.
-
Apr 11, 2024
ViGeneron Launches Clinical Trial of Gene Therapy for RP Caused by CNGA1 Mutations
Research NewsThe gene therapy is administered using a less-invasive intravitreal injection.
-
Mar 25, 2024
Foundation NewsCollaboration will add a new multi-gene cohort of patients living with inherited retinal diseases. Data insights from the new study cohort will inform the future clinical trial design for BlueRock’s pipeline of cell therapies for treating blindness.
-
Mar 25, 2024
Beacon StoriesAdopted into a musical family, Miles Hoyt picked up a guitar at just four years old, and he hasn’t stopped playing since. Now Miles, who has Stargardt disease, and his parents are using music to bring their community together to raise funds for blinding diseases with their Raising Our Sights fundraiser, Smiles for Miles.
-
Feb 15, 2024
Foundation NewsThe May 9th gala will raise awareness and fund research leading to treatments and cures for blinding retinal diseases.